E
E. Amour
Publications - 7
Citations - 424
E. Amour is an academic researcher. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 5, co-authored 7 publications receiving 297 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Arnaud Scherpereel,Julien Mazieres,Laurent Greillier,Sylvie Lantuejoul,Pascal Do,O. Bylicki,Isabelle Monnet,Romain Corre,Clarisse Audigier-Valette,M. Locatelli-Sanchez,Olivier Molinier,Florian Guisier,Thierry Urban,Catherine Ligeza-poisson,David Planchard,E. Amour,Franck Morin,Denis Moro-Sibilot,Gérard Zalcman,Didier Debieuvre,Sandrine Hiret,Jacques Cadranel,Séverine Fraboulet-Moreau,Delphine Carmier +23 more
TL;DR: This multicentre randomised, non-comparative, open-label, phase 2 trial aimed to prospectively assess the anti-PD-1 monoclonal antibody alone or in combination with anti-cytotoxic T-lymphocyte protein 4 (CTLA-4) antibody in patients with malignant pleural mesothelioma.
Journal ArticleDOI
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial
Arnaud Scherpereel,Julien Mazieres,Laurent Greillier,Pascal Do,O. Bylicki,Isabelle Monnet,Romain Corre,Clarisse Audigier-Valette,M. Locatelli-Sanchez,Olivier Molinier,Luc Thiberville,Thierry Urban,Catherine Ligeza-poisson,David Planchard,E. Amour,Franck Morin,Denis Moro-Sibilot,Gérard Zalcman +17 more
TL;DR: Primary endpoint was DCR at 12 weeks with a blinded independent central review (BICR), and patients were to be randomized with one-step Fleming procedure, H0 P 40%, with 95% powe...
Journal ArticleDOI
Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)
G. Zalcman,J. Mazieres,Laurent Greillier,Solenn Brosseau,Sylvie Lantuejoul,P. Do,O. Bylicki,Isabelle Monnet,Romain Corre,Clarisse Audigier-Valette,M. Locatelli-Sanchez,Olivier Molinier,Florian Guisier,Thierry Urban,David Planchard,C. Ligeza-Poisson,E. Amour,Franck Morin,D. Moro-Sibilot,Arnaud Scherpereel +19 more
TL;DR: The durable efficacy of Nivo & Nivo+Ipi in MPM in confirmed, with 1/4 and 1/3 of pts alive at 2 yrs respectively, with significantly worse survival when the TGKr definition of HPD is used.
Journal ArticleDOI
LBA58_PRSecond or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial
Gérard Zalcman,J. Mazieres,Laurent Greillier,Sylvie Lantuejoul,P. Do,O. Bylicki,Isabelle Monnet,Romain Corre,Clarisse Audigier-Valette,M. Locatelli-Sanchez,Olivier Molinier,Luc Thiberville,Thierry Urban,David Planchard,C. Ligeza-Poisson,E. Amour,Franck Morin,D. Moro-Sibilot,Arnaud Scherpereel +18 more
Journal ArticleDOI
[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].
Xavier Mignard,Martine Antoine,Denis Moro-Sibilot,Charles Dayen,Bertrand Mennecier,Radj Gervais,E. Amour,Bernard Milleron,Franck Morin,Gérard Zalcman,Marie Wislez +10 more
TL;DR: Le durvalumab est un anticorps monoclonal bloquant l’interaction PD-L1/PD-1 entre lymphocytes T et cellules tumorales, ayant montre des reponses durables et une toxicite acceptable en phase I/II dans les cancers bronchiques non a petites cellules (CBNPC) metastatiques.